Patients with axial spondyloarthritis (axSpA) commonly experience cardiovascular (CV) comorbidities. There is a need to holistically assess a patient, including considerations for managing disease activity and understanding the safety profile of available therapies as it relates to comorbidities. Join Marina Magrey, MD as she provides insight on this topic for holistic patient-centered care. Please provide feedback on the session using this link https://bit.ly/3j4pA6u
New to RheumNow? Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. In this episode, Dr Jack Cush reviews the news, journal articles and FDA warnings from the past week on RheumNow.com A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections...
Merry Christmas and Happy Holidays from RheumNow. Dr. Jack Cush tells his podcast story - the genesis, keys to success and recommendations on how to get into podcasting - for teaching, practice, fun or influence.
There is a significant burden of disease associated with JPsA and ERA, with patients experiencing structural damage progression, risk of disability, and comorbidities that may persist into adulthood. This presentation led by Hermine Brunner, MD educates on the importance of early recognition and management.
Drs. Jack Cush and Martin Bergman gather to review the topic of treat-to-target (T2T) management in rheumatology. Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022. You can register and learn more about the meeting at: https://r-w-c-s.com/2022/
JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kay Infliximab Drug Monitoring in PsA, RA, AxSpA: Dr. Pedro Castillo Lupus and Pregnancy: Dr. Sheila Reyes Secukinumab Effect on CV Risks in PsA, axSpA: Dr. Sheila Reyes